Shares of the biopharmaceutical company Enochian Biosciences Inc. (ENOB) are rising 5.51% to trade at $5.55 at the commencement of today’s regular session. Enochian stock has risen as high as 16.73% to $6.14 on the stock charts in the premarket session. ENOB stock closed the Friday session at $5.26, increasing 6.26% on the day. ENOB stock traded for 0.58 million shares, lower than the 2.19 million average volume over the last three months. During the last trading session, the ENOB stock oscillated between a price range of $4.88 and $5.31. EPS for the ENOB stock was negative 0.29.

ENOB is up 4.78% in the last five sessions and gained 22.33% over the past month while jumping 78.31% so far this year. Currently, ENOB’s 50-day moving average is $4.49, higher than its 200-day moving average of $3.67. Furthermore, the ENOB stock is currently trading at an RSI of 54.91. The ENOB stock is rising sharply on news that FDA has accepted its Pre-IND request for its treatment of hepatitis.

Which therapy is ENOB trying to develop?

Enochian is a biopharmaceutical company focusing on the development of gene-modified cellular and immune therapies for the potential cure and treatment of deadly diseases. In addition to HIV/AIDS, Hepatitis B, Corona and Influenza viruses, and Oncology, ENOB’s gene-modified cell, and immune therapy platforms might also be useful for other indications.

The FDA accepted an IND (Investigational New Drug) request from Enochian for a potential cure of hepatitis B virus (HBV), announced the company in a press release today.

• Commentary will be provided in writing this fall.
• A proof-of-concept study performed in chimeric mice substantiated ENOB’s pre-IND request.
• Researchers have deemed ENOB’s study as the best way to evaluate HBV cure using an animal model.
• A request from ENOB for feedback on its Hepatitis B program was accepted by the FDA.
• The agency’s suggestions were appreciated by ENOB.
• ENOB’s move toward pre-IND is also brought about by Hijack RNA, which exhibits an intriguing mechanism of action.
• In addition to being a potential platform technology for coronaviruses (including COVID-19), influenza and HBV, the mechanism is being explored as a potential technology for combating HIV.
• With the impressive results of the premier animal model, ENOB has great hope of developing a commercial product that may cure chronic liver damage in approximately 350 million people per year, killing nearly 1 million.

What has ENOB recently shared about HBV therapy?

Enochian (ENOB) co-founder and inventor Serhat Gumrukçu, director of Seraph Research Institute (SRI), has recently presented data showing the daily decline of HBV to the point where it cannot be detected by day eight. The liver and other tissues were not found to be toxic by ENOB. ENOB presented its findings during the prestigious International Liver Conference last month.